TP53BP1 and neoplasm: In addition to GI toxicity to curative RT, we analyzed whether the γ-H2AX and 53BP1 foci assays allowed to discriminate between tumor stage (II, III or IV, Fig. 5 and Additional file 1: Figure S4) or TRG after RT of RC patients (Fig. 6).